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Abstract
Background: Protein kinase C (PKC) in the spinal cord appears to mediate chronic injury-induced
pain, but not acute nociceptive pain. Muscle insult results in increased release of glutamate spinally,
and hyperalgesia that is reversed by spinal blockade of NMDA and non-NMDA glutamate
receptors. Therefore, we hypothesized that spinal activation of PKC 1) mediates the late phase of
hyperalgesia 1 week after muscle insult, and 2) produces mechanical hyperalgesia through activation
of NMDA and non-NMDA glutamate receptors.
Results: Rats were implanted with intrathecal catheters for delivery of drugs directly to the spinal
cord. Mechanical withdrawal thresholds of the paw were determined using von Frey filaments.
Intrathecal phorbol 12,13 dibutyrate (PDBu) produced a dose-dependent decrease in the
mechanical withdrawal threshold of the paw that was prevented by pretreatment with the PKC
inhibitor, GF109203X. Pretreatment with an NMDA receptor antagonist (AP5) or a AMPA/kainate
receptor antagonist (NBQX) prevented the decrease in mechanical withdrawal threshold by PDBu.
Two injections of acidic saline in the gastrocnemius muscle decreased the mechanical withdrawal
thresholds of the paw bilaterally 24 h and 1 week after the second injection. However, blockade
PKC in the spinal cord had no effect on the decreased withdrawal thresholds of the paw when
compared to vehicle controls.
Conclusion: Spinal activation of PKC produces mechanical hyperalgesia of the paw that depends
on activation of NMDA and non-NMDA receptors. Chronic muscle-induced mechanical
hyperalgesia, on the other hand, does not utilize spinal PKC.
Background
Protein kinase C activation involves translocation from
the cytosol to binding domains at cell membranes of dor-
sal horn neurons of the spinal cord [1,2]. There are at least
twelve isoforms of PKC. Several of these isoforms are con-
centrated in the superficial laminae of the dorsal horn, an
anatomical indication that these PKC isoforms play a
potential role in nociceptive signaling. In particular, PKCβ
I, PKCβ II, and PKCα are found in cell bodies within the
superficial dorsal horn, where PKCγ is primarily found in
cell bodies in lamina IIii [2,3]. PKC is involved in many
aspects of cellular sensitization, including modulation of
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channel conductivity by phosphorylation, increased traf-
ficking of receptors to the cell membrane, and release of
excitatory neurotransmitters [4-9].
Activation of PKC with phorbol esters in the spinal cord
decreases heat and mechanical withdrawal thresholds,
increases glutamate release in the spinal cord, and sensi-
tizes spinothalamic tract and other dorsal horn neurons
[9-12]. PKC is involved in animal models of both neuro-
pathic and inflammatory pain. In rats with neuropathic
pain produced by spinal nerve ligation or sciatic nerve
ligation the mechanical hyperalgesia is reversed by
intrathecally administered PKC inhibitors and reduced in
PKCγ knockout mice when compared to wild-type mice
[3,13-15]. Similarly, spinal blockade of PKC reverses the
hyperalgesia induced by subcutaneous formalin, pancrea-
titis, thermal injury, cutaneous capsaicin, diabetic neurop-
athy and subcutaneous bee venom [10,16-20]. In PKCγ
knockout mice acute responses to thermal and mechani-
cal stimuli are similar to wild-type mice [3], suggesting a
role for PKC in more chronic injury-induced pain, but not
in acute nociceptive pain.
Activation of cAMP (cyclic adenosine monophosphate)
spinally activates intracellular pathways that results in
sensitization of spinal neurons and mechanical hyperal-
gesia. A decrease in mechanical paw withdrawal threshold
produced by intramuscular injections of acid or capsaicin
is reversed by spinal blockade of cAMP-PKA pathway in
the spinal cord 24 h, but not 1 week, following muscle
insult [21,22]. These studies demonstrate a role of the
cAMP-PKA pathway in the early phase of development,
but not in the later phase. We further show an increased
release of glutamate in the spinal dorsal horn, and that
blockade of NMDA and non-NMDA glutamate receptors
1 week after muscle insult [23,24]. Since PKC appears to
mediate more chronic pain conditions we hypothesized
that activation of PKC mediates the late phase of hyperal-
gesia 1 week after muscle insult. We further hypothesized
that activation of PKC in the spinal cord produces
mechanical hyperalgesia through activation of NMDA
and non-NMDA glutamate receptors.
Results
Intrathecal injection of PDBu decreased the mechanical
withdrawal threshold bilaterally in a dose-dependent
manner (Fig. 1). PDBu produces a significant decrease in
paw withdrawal threshold for 60–90 minutes after
intrathecal injection (F4,13 = 9.8, p = 0.001, P = 0.001). A
significant decrease was observed for doses ranging from
1–10 nmol/10 µl after injection of PDBu when compared
Time course of effects of intrathecal treatment with PDBu, 0.1–10 nmol/10 ml, compared to vehicle and the inactive com- pound 4-α-PDBu Figure 1
Time course of effects of intrathecal treatment with PDBu, 0.1–10 nmol/10 ml, compared to vehicle and the inactive com-
pound 4-α-PDBu. The withdrawal thresholds for 1, 3 and 10 nmol PDBu groups are significantly less than vehicle controls or 4-
a-PDBu. Inset shows that GF109203X. 0.5 nmol/10 ml, significantly prevents the decreases in withdrawal thresholds that nor-
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to vehicle controls (1 nmol p = 0.004; 3 nmol p = 0.02; 10
nmol p = 0.002)(Fig. 1).
Pretreatment with the PKC inhibitor (0.5 nmol/10 µl)
GF109023X prevented the decrease in mechanical with-
drawal threshold produced 30 min after intrathecal injec-
tion of PDBu (1–10 nmol/10 µl)(p = 0.009) when
compared to PDBu alone (Fig. 1). Pretreatment with 60
nmol/10 µl NPC15437 or 25 nmol/10 µl chelerythrine
chloride had no effect on the 10 nmol/10 µl PDBu-
induced decrease in mechanical withdrawal threshold.
Mechanical withdrawal threshold for NPC15437 + PDBu
were: 67 mN 15 min; 77 mN 30 min; 49 mN 45 min; 31
mN 60 min. Mechanical withdrawal threshold for cheler-
ythrine chloride + PDBu were: 20 mN 15 min; 57 mN 30
min; 14 mN 45 min; 27 mN 60 min. The mechanical
withdrawal thresholds after intrathecal injections of 4α-
PDBu (1–10 nmol/10 µl) were significantly greater than
those following PDBu injections (1–10 nmol/10 µl, p =
0.0001). Figure 1 shows the time course of effect for 10
nmol 4α-PDBu. Withdrawal threshold for the 3 nmol
dose of 4α-PDBu were: 104 mN 15 min; 106 mN 30 min;
112 mN 45 min; 120 mN 60 min. Withdrawal threshold
for the 1 nmol dose of 4α-PDBu were: 137 mN 15 min;
148 mN 30 min; 143 mN 45 min; 126 mN 60 min.
A significant difference between groups occurred for the
changes in mechanical withdrawal threshold for the ani-
mals pretreated intrathecally with the glutamate receptor
antagonists or vehicle for the 3 nmol dose of PDBu (χ2 =
10.4, p = 0.005) and the 10 nmol dose of PDBu (χ2 = 7.4,
p = 0.02). Specifically, pretreatment with AP5 prevented
the decrease in mechanical withdrawal threshold pro-
duced by PDBu when compared to animals receiving
vehicle (3 nmol/10 µl n = 5, p = 0.006; 10 nmol/10 µl; n
= 5, p = 0.006). Similarly, pretreatment with the non-
NMDA receptor antagonist NBQX prevented the decrease
in mechanical withdrawal threshold following PDBu
when compared to vehicle controls (3 nmol/10 µl, n = 5,
p = 0.006; 10 nmol/10 µl, n = 8, p = 0.03). There was a
smaller effect of NBQX on the hyperalgesia produced by
10 nmol PDBu when compared to that produced by the 3
nmol dose (F1,12 = 4.6, p = 0.053).
Two intramuscular injections of pH 4 saline 5 days apart
produced a bilateral decrease in mechanical withdrawal
thresholds 24 h and 1 week after the second injection. Spi-
nal blockade of PKC with GF109023X (0.05–0.5 nmol/10
µl) had no effect on the decreased mechanical withdrawal
threshold when delivered intrathecally 24 h or 1 week
after the second injection of acidic saline compared to
vehicle controls (Fig. 3).
Discussion
The current study demonstrates that activation of PKC in
the spinal cord produces a decrease in mechanical with-
drawal threshold that is prevented by blockade of PKC
with GF109023X. This PKC-mediated decrease in
mechanical withdrawal threshold is consistent with previ-
ous data showing a similar decrease in mechanical with-
drawal threshold by spinal activation of PKC [9,10]. We
further show that the decreased mechanical withdrawal
threshold produced by spinal activation of PKC is pre-
vented by spinal blockade of NMDA receptors and AMPA/
kainate receptors. There are several possibilities that could
explain how PKC activation produces its effects through
glutamate receptors. First, PKC could produce increased
release of glutamate into the spinal cord resulting in con-
tinued activation of glutamate receptors. Spinal activation
of PKC increases release of glutamate in vivo [9] and in
vitro [12], and formalin-induced release of glutamate is
prevented by blockade of PKC [17]. Further, spinal activa-
tion of PKC enhances responses of dorsal horn neurons to
NMDA and AMPA agonists [12,25,26]. Thus increased
glutamate release and increased activation of glutamate
receptors are likely results of activation of PKC.
Second, PKC could phosphorylate the NMDA or AMPA/
kainite receptor to result in increase channel conductance
or potentiation of glutamate gated currents that would be
manifested as an increased excitability of the neuron [27-
30]. Activation of PKC sensitizes dorsal horn neurons
exhibited as an increased spontaneous firing, increased
response to peripherally applied mechanical stimuli [31],
and an increased response to glutamate and NMDA [12].
Further, PKC decreases Mg2+ affinity in the NMDA recep-
tor pore which increases the probability of the channel
opening [26]. Indeed, in animal models of pain there is an
increase in phosphorylation of the NR1 subunit and
GlurR1 subunit that likely depends on activation of PKC
[32-36].
Third, phosphorylation of NMDA or AMPA receptor sub-
units could increase trafficking and insertion of receptors
into the cell membrane and synapse. Phosphorylation of
NR1 by PKC increases surface expression of NMDA recep-
tors, increases delivery of NMDA receptors to the surface
and to the synapse [28,37,38]. The AMPA receptor subu-
nits are also phosphorylated by PKC [27,29]. However,
the functional role of phosphorylation of AMPA receptor
subunits in receptor trafficking has not been tested to
date. Thus, increased phosphorylation of glutamate recep-
tors could result in an increased channel conductance and
an increased number of receptors available synaptically
resulting in increased excitation of the nociceptive spinal
neurons.Molecular Pain 2006, 2:13 http://www.molecularpain.com/content/2/1/13
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Lastly, PKC decreases efficacy of inhibitory neurotrans-
mitters on spinothalamic tract neurons, which would be
manifested as an increased excitation. For example intra-
dermal injection of capsaicin reduces the inhibition of
spinothalamic tract neurons normally produced by elec-
trical stimulation of the periaqueductal gray or by GABA;
this loss of inhibition is prevented by spinal blockade of
PKC [39]. Similarly, the inhibition of calcium channels by
µ-opioid agonists in the spinal dorsal horn of rats is pre-
vented by inhibition of PKC [40]. Thus, increased PKC
activity reduces normal inhibition within the spinal cord.
Thus, spinal activation of PKC could result in increased
glutamate release, increased channel conductance of
glutamate receptors, increased number of glutamate
receptors in the membrane, and decreased inhibition.
Taken together this would result in increased excitability
of neurons that is manifested as decreased withdrawal
thresholds to noxious stimuli.
Surprisingly, spinal blockade of PKC had no effect on the
decreased mechanical withdrawal threshold induced by
repeated intramuscular acid injections suggesting PKC
Time course of effects of intrathecal pretreatment with AP5 or NBQX on the decreased withdrawal threshold induced by  PDBu, for 3 nmol dose (top graph) and for the 10 nmol dose (bottom graph) Figure 2
Time course of effects of intrathecal pretreatment with AP5 or NBQX on the decreased withdrawal threshold induced by 
PDBu, for 3 nmol dose (top graph) and for the 10 nmol dose (bottom graph). Data are represented as the mean +/- S.E.M. *, 
significantly greater than vehicle control
10 nmol PDBu
Time (after PDBu)
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activation in the spinal cord does not maintain the hyper-
algesia once developed. However, the current study did
not determine the role of PKC activation in the develop-
ment of the hyperalgesia and future studies should inves-
tigate if pre-treatment with PKC inhibitors prevents
development of hyperalgesia. The lack of effect of PKC on
the maintenance, however, is inconsistent with previous
studies that show nocifensive behaviors and dorsal horn
neuron sensitization are reversed by PKC inhibitors in
models of inflammatory and neuropathic pain
[3,10,11,13-20,41]. Mice lacking PKCγ show a significant
deficit in the hyperalgesia associated with neuropathic
pain and the second phase of the formalin test [3]. Fur-
ther, the number of neurons staining for PKCγ increases in
the spinal cord in animals with neuropathic pain [42],
PKCγ staining increases in the spinal cord following CFA-
paw inflammation that lasts through 14 days [43], PKCβ
II is increased in the cell membranes in the spinal cord fol-
lowing CFA-inflammation through 14 days [2], and phos-
phorylated PKC increased in the spinal cord after thermal
Effects of GF109203X, compared to vehicle, on the decreased withdrawal thresholds 24 h and 1 week after repeated intramus- cular acid injections Figure 3
Effects of GF109203X, compared to vehicle, on the decreased withdrawal thresholds 24 h and 1 week after repeated intramus-
cular acid injections. Data are the mean +/- S.E.M.
1 week
Time (post drug)
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injury [44]. Taken together, it appears that PKC is
involved in long-term hyperalgesia, and that PKCγ and
PKCβ II may be important in the processing of nociceptive
information in chronic hyperalgesia. However, blockade
o f  P K C  i n  t h e  s p i n a l  c o r d  h a d  n o  e f f e c t  o n  t h e  a c i d -
induced model of muscle pain. This model is unique;
there is no detectable injury to the peripheral muscle after
injection of acidic saline and hyperalgesia is maintained
by changes in the central nervous system [45]. Thus, dif-
ferences could be related to the dependence on continued
primary afferent input to the spinal cord. Differences
could also result from the type of tissue activated: i.e. cuta-
neous vs. deep somatic tissue. Prior studies utilize animal
models with cutaneous inflammation, i.e. formalin, cap-
saicin, paw carrageenan, paw CFA, cutaneous thermal
injury, or nerve injury which likely includes cutaneous
afferent damage. The mechanisms responsible for cutane-
ous pain are distinctly different from those related to mus-
cle pain. In support, we previously show that capsaicin
injected into cutaneous tissue results in short lasting
(hours) mechanical hyperalgesia while capsaicin injected
into muscle or joint results in long-lasting mechanical
hyperaglesia (days to weeks) [21]. Formalin injected into
skin of the back resulted in fos expression in laminae I-V;
whereas formalin injected into the paraspinal muscles did
not result in fos staining in laminae II [46]. Formalin
injection into the muscle, when compared to the skin,
resulted in greater fos expression in brain areas known to
mediate descending facilitation of nociception, i.e. amy-
gdala, and the ventrolateral periaqueductal gray II [46].
Thus different anatomical pathways could mediate differ-
ences between muscle pain and those in other cutaneous
pain models.
The current study showed that 2 or the 3 PKC inhibitors
tested were ineffective against PDBu, an activator of PKC.
GF109023X has been shown to be more efficacious in
inhibition if substance P-induced nocifensive behaviours
compared to chelerythrine chloride [47]. In the current
study, GF109023X significantly reduced the effects of 10
nmol PDBu; while chelerythrine chloride and NPC15437
had no effect on the reduction in withdrawal thresholds
produced by NPC15437. It is possible, based on the dif-
ferences in efficacy of the PKC inhibitors, that an effect
could be observed if tested against lower doses of PDBu.
Of note, the majority of the previous studies did not test
the PKC inhibitor utilized against the agonist. The doses
of PKC inhibitors utilized in the current study, were simi-
lar or higher than those utilized previously [47-50]. How-
ever, dosing with chelerythrine chloride and NPC15437
were limited by solubility for in vivo delivery of the antag-
onist to the spinal cord intrathecally. Our prior study
using microdialysis was able prevent the effects of activa-
tion of PKC with NPC15437 [10]. This different method-
ology may be able to deliver a higher effective dose closer
to the neurons than a single intrathecal bolus since it uti-
lizes continued slow diffusion into the spinal cord paren-
chyma.
Although the current data support that blockade of gluta-
mate receptors prevents the onset of PKC-induced hyper-
algesia, it is possible that these glutamate receptor
antagonists were analgesic on their own and thus masking
the effects of PDBu. One limitation to testing mechanical
thresholds with von Frey filaments is that we cannot
detect an analgesic effect as the cut-off for withdrawal is
essentially our baseline response before injury. The doses
of AP5 and NBQX used in the current study, however,
have no significant effects on motor behaviors 15–120
minutes after delivery of the drug intrathecally [23,51,52].
Further, intrathecal treatment using AP5 (10 nmol), simi-
lar doses to those in used in the current study, had no
effect on the hyperalgesia that develops after plantar inci-
sion [52,53]. These data argue against the analgesic poten-
tial of these antagonists at the doses utilized, and thus
support our conclusions that PDBu produces its effects
through activating NMDA and non-NMDA receptor
antagonists.
Conclusion
Activation of the PKC pathway in the spinal cord produces
mechanical hyperalgesia that is prevented by blockade of
PKC, NMDA, or AMPA/kainite receptors. However, activa-
tion of PKC in a model of non-inflammatory muscle pain
has no role in the maintenance of the hyperalgesia.
Methods
All experiments were approved by the animal care and use
committee at the University of Iowa and are in accordance
with NIH guidelines and the International Association for
the Study of pain. A total of 123 male Sprague-Dawley rats
(250–450 g; Harlan, St. Louis, MO) were utilized in these
studies.
Intrathecal catheter placement
Animals were placed under general anesthesia using 2%
halothane. Catheters (32 G polyeurethane tubing, 10 cm;
ReCathCo, Allison Park, PA) were attached to PE10 tubing
(0.28 mm ID, polyeurethane, 10 cm; Becton Dickson and
Company, Sparks, MD) and threaded through a 23 G nee-
dle. The 23 G needle was inserted into the intrathecal
space between L5/L6 until a tail flick was elicited confirm-
ing placement intrathecally. The tubing was then
advanced 4 cm so the tip was located in the lumbar
enlargement. The catheter was secured to the fascia, the
PE10 tubing was threaded out between the shoulder
blades, and the incision was closed with silk sutures. Ani-
mals were allowed to recover from anesthesia under
observation prior to testing 3–5 days later.Molecular Pain 2006, 2:13 http://www.molecularpain.com/content/2/1/13
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Mechanical withdrawal threshold
Before behavioral testing, rats were placed in clear Plex-
iglas™ chambers on a wire mesh elevated surface to accli-
mate for 30–40 min. Withdrawal thresholds from
mechanical stimuli of von Frey filaments of ascending
bending force (from 10.0 to 494.6 mN) were applied
twice to the plantar surface of the bilateral hind paws. A
positive response was defined as withdrawal from the von
Frey filament. Confirmation of threshold was tested by
examining the filament above and below the withdrawal
response. Test-retest reliability was previously determined
for this method (r2 = 0.7; p = 0.007) [54]. A decrease in
mechanical withdrawal threshold is interpreted as
mechanical hyperalgesia.
Drug administration
Drugs were administered to awake animals through
intrathecal (i.t.) catheters. A 30 G drug delivery needle
attached to a length of PE50 tubing was affixed to the end
of a 50 µl Hamilton syringe for drug administration
through i.t. catheters. Drugs were delivered as a 10 µl
bolus. Following the completion of all experiments cor-
rect catheter placement was confirmed by intrathecal
injection of 10 µl of 2% lidocaine followed by 10 µl meth-
ylene blue dye. A catheter was considered correctly placed
if there was loss of sensory and motor function after lido-
caine and methylene blue dye staining included the L4-L6
spinal segments.
Drugs
During the course of these experiments the following
drugs were used: phorbol 12,13 dibutyrate (PDBu; Calbi-
ochem, LaJolla, CA; 0.1 nmol/10 µl, 1 nmol/10 µl, 3
nmol/10 µl, 10 nmol/10 µl), a phorbol ester that directly
activates the PKC pathway by mimicking diacylglycerase;
4α PDBu (Calbiochem, La Jolla, CA; 1 nmol/10 µl, 3
nmol/10  µl, 10 nmol/10 µl), the inactive isoform of
PDBu; GF109203X (Sigma Chemical Co., St. Louis, MO;
0.5 nmol/10 µl, 0.15 nmol/10 µl, 0.05 nmol/10 µl), a
non-selective PKC inhibitor [14,47]; chelytherine chlo-
ride (Sigma Chemical Co., St. Louis, MO; 25 nmol/10 µl),
a non-selective PKC inhibitor; NPC15437 (60 nmol/10
µl) a non-selective PKC inhibitor; AP5 (Sigma Chemical
Co., St. Louis, MO; 20 nmol/10 µl), an N-methyl-D-aspar-
tate (NMDA) receptor antagonist; NBQX (Sigma Chemi-
cal Co., St. Louis, MO; 10 nmol/10 µl), an alpha-amino-
3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kai-
nate receptor antagonist [23].
Induction of muscle-induced mechanical hyperalgesia
Two single 0.1 ml injections of saline (pH = 4), 5 days
apart, were injected into the left gastrocnemius muscle of
lightly anesthetized rats (2% halothane) [45].
Experimental Protocol
Experiment 1
Phorbol 12,13 dibutyrate (PDBu) (0.1 nmol/10 µl, n = 5;
0.3 nmol/10 µl, n = 4; 1.0 nmol/10 µl, n = 4; 3.0 nmol/10
µl, n = 5; 10.0 nmol/10 µl, n = 5) was injected intrathe-
cally into the spinal cord. Paw withdrawal threshold was
measured before and 30 min after intrathecal injection of
PDBu. An equivalent volume of vehicle (saline with 10%
DMSO) was injected instead of PDBu as a control (n = 5).
As an additional control, rats were injected the inactive
compound, 4α-PDBu (1 nmol/10 µl, n = 4; 3 nmol/10 µl,
n = 4; 10 nmol/10 µl, n = 4).
Experiment 2
The ability of the PKC inhibitors GF109023X (0.5 nmol/
10 µl), NPC15437 (60 nmol/10 µl, n = 4), and cheleryth-
rine chloride (25 nmol/10 µl, n = 2) to block the
decreased mechanical withdrawal threshold produced by
PDBu (10.0 nmol/10 µl, n = 5; 3.0 nmol/10 µl, n = 5; 1.0
nmol/10 µl, n = 5) was tested. Ten minutes prior to PDBu
administration a single dose of PKC inhibitor was given.
Mechanical withdrawal threshold was tested before, 30
and 45 min after PDBu injection.
Experiment 3
The ability of AP5, an NMDA receptor antagonist, and of
NBQX, an AMPA/kainate receptor antagonist, to block the
decreased mechanical withdrawal threshold of the phor-
bol ester PDBu (3 nmol/10 µl and 10 nmol/10 µl) was
tested. Initial experiments tested the effects of AP5 and
NBQX on the 10 nmol/10 µl. Because of the increased var-
iability with NBQX with the highest dose of PDBu, we
tested a lower dose of 3 nmol PDBu. After baseline
mechanical thresholds were determined, AP5 or NBQX
were administered intrathecally 10–15 min prior to
intrathecal PDBu. Rats were randomly assigned to the fol-
lowing groups: 1) 20 nmol/10 µl AP5 pretreatment to
intrathecal 10 nmol/10 µl PDBu (n = 5), 2) 10 nmol/10
µl NBQX pretreatment to intrathecal 10 nmol/10 µl PDBu
(n = 8), 3) vehicle pretreatment (saline) to intrathecal 10
nmol/10 µl PDBu (n = 5), 4) 20 nmol/10 µl AP5 pretreat-
ment to intrathecal 3 nmol/10 µl PDBu (n = 5), 5) 10
nmol/10 µl NBQX pretreatment to intrathecal 10 nmol/
10 µl PDBu (n = 5), and 6) vehicle pretreatment (saline)
to intrathecal 10 nmol/10 µl PDBu (n = 5). Paw with-
drawal from von Frey filament stimuli was recorded bilat-
erally before injection and 30 min after intrathecal
phorbol ester injection.
Experiment 4
The ability of the PKC inhibitor GF109023X (0.5 nmol/10
µl, 0.15 nmol/10 µl/10 µl, 0.05 nmol/10 µl) to block the
bilateral secondary mechanical hyperalgesia produced by
repeated intramuscular injections of pH 4 saline was
tested in two separate groups either 24 h or 1 week afterMolecular Pain 2006, 2:13 http://www.molecularpain.com/content/2/1/13
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the second intramuscular injection of acidic saline.
Intrathecal catheters were implanted 3–5 days prior to the
first injection of acidic saline and vehicle or GF109023X
was delivered cumulatively to the spinal cord dorsal horn
in 1 h intervals. Withdrawal thresholds were assessed
before injection 1, before injection 2, 24 h after intramus-
cular injection of acidic saline, and after intrathecal injec-
tion of vehicle (saline, n = 5) or GF109023X (0.05 nmol/
10 µl, 0.15 nmol/10 µl, 0.5 nmol/10 µl (n = 8). With-
drawal thresholds were assessed before injection 1, before
injection 2, 1 week after intramuscular injection of acidic
saline and after intrathecal injection of saline (n = 5),
GF109023X (0.05 nmol/10 µl, 0.15 nmol/10 µl, 0.5
nmol/10 µl (n = 4). The tester was blinded to treatment
group. Mechanical withdrawal threshold was assessed 15,
30, 45, and 60 min after the injection of drug or vehicle.
Data analysis
Paw withdrawal thresholds were compared across time,
and between groups, using statistical analysis with a
repeated measures analysis of variance (ANOVA). Post
hoc testing between individual groups was done using a
Tukey's test. Significance was determined at p ≤ 0.05. Data
is presented as the mean +/- S.E.M.
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